2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-182711
    SCR0911 1379615-30-1
    SCR0911 is an inhibitor of mycobacterial cytochrome bcc oxidase and Plasmodium falciparum cytochrome bc1. SCR0911 disrupts oxidative phosphorylation by binding to mycobacterial cytochrome bcc, binds to the Qi site of Plasmodium falciparum cytochrome bc1, inhibits mycobacterial cell growth and ATP synthesis, and exhibits broad-spectrum anti-mycobacterial and anti-malarial activities. SCR0911 can be used in research related to tuberculosis, malaria, and isolated persistent hypermethioninemia (iph).
    SCR0911
  • HY-182754
    SARS-CoV-2 Mpro-IN-57 3031240-80-6 98%
    SARS-CoV-2 Mpro-IN-57 is an irreversible SARS-CoV-2 main protease inhibitor with an IC50 of 0.41 μM and a Kd of 247.37 nM. SARS-CoV-2 Mpro-IN-57 forms a covalent bond with the key amino acid residue Cys145 in SARS-CoV-2 main protease via its -CN group. SARS-CoV-2 Mpro-IN-57 can be used for the research of COVID-19.
    SARS-CoV-2 Mpro-IN-57
  • HY-182784
    Antibacterial agent 336
    Antibacterial agent 336 is an antibacterical agent with broad-spectrum inhibitory activity against Gram-negative and Gram-positive bacteria. Antibacterial agent 336 binds tightly via its pyridine group to the carboxyl group, Lys-465 residue, and Leu-480 residue of the MsbA protein, interfering with bacterial outer membrane synthesis, and exerts concentration-dependent bactericidal activity against bacterial. Antibacterial agent 336 has low cytotoxicity to normal human liver cells. Antibacterial agent 336 can be used for the research of bacterial infections.
    Antibacterial agent 336
  • HY-182798
    Antibacterial agent 337
    Antibacterial agent 337 is an antibacterial agent. Antibacterial agent 337 specifically interacts with PG in bacterial cell membranes, triggering membrane disruption, membrane depolarization, increased permeability, cytoplasmic leakage, ROS accumulation and rapid bacterial death. Antibacterial agent 337 inhibits biofilm formation and disrupts mature biofilms. Antibacterial agent 337 exhibits potent in vivo antibacterial efficacy in a mouse model of Staphylococcus aureus skin abscess. Antibacterial agent 337 can be used in studies of Gram-positive bacterial infections, including methicillin-resistant Staphylococcus aureus infections, vancomycin-resistant Enterococcus faecalis infections and bacterial biofilm infections.
    Antibacterial agent 337
  • HY-182816
    Topoisomerase I-IN-22 3080330-34-0
    Topoisomerase I-IN-22 is an inhibitor of MRSA DNA Topoisomerase I with an IC50 of 0.85 μg/mL. Topoisomerase I-IN-22 can specifically disrupt the cell membrane structure of MRSA, enter the interior of bacteria and inhibit the activity of DNA Topoisomerase I, thereby interfering with the processes of DNA replication and transcription. Topoisomerase I-IN-22 can be used for the research of MRSA infection.
    Topoisomerase I-IN-22
  • HY-182823
    N-Nitrosovancomycin 155386-25-7 98%
    N-Nitrosovancomycin is an antibacterial agent and an N-terminal nitrosated derivative of vancomycin. N-Nitrosovancomycin exhibits antibacterial activity against Gram-positive bacteria in vitro, but shows no activity against Gram-negative E. coli. The modified N-terminal amino group of N-Nitrosovancomycin cannot be protonated, yet the compound still retains in vitro antibacterial activity. N-Nitrosovancomycin can be used in studies related to Gram-positive bacterial infections.
    N-Nitrosovancomycin
  • HY-182924
    Jun15702 98%
    Jun15702 is a PROTAC degrader targeting the capsid protein VP1 of enterovirus D68. Jun15702 recruits the Cereblon (CRBN) E3 ligase and activates the ubiquitin-proteasome pathway. Jun15702 inhibits viral entry and exerts inhibitory effects during the early, middle and late stages of viral replication. Jun15702 exhibits antiviral activity against multiple wild-type enterovirus D68 strains, and also shows submicromolar antiviral activity against the Pleconaril (HY-19952)-resistant enterovirus D68 variant rMO-VP1 F159V. Jun15702 can be used in studies related to enterovirus D68 (EV-D68) infection.
    Jun15702
  • HY-183008
    BSF2 179118-06-0 98%
    BSF2 is a anti-Leishmania agent. BSF2 modulates gene expression linked to ubiquitination, chromatin remodeling, and peroxisomal membrane transport pathways in Leishmania braziliensis. BSF2 downregulates TNF, IL-17, NF-κB, and Toll-like receptor pathways in Leishmania-infected macrophages. BSF2 exerts leishmanicidal activity against intracellular Leishmania braziliensis amastigotes. BSF2 can be used for the research of american tegumentary leishmaniasis.
    BSF2
  • HY-183009
    Pf20S-IN-1 98%
    Pf20S-IN-1 is a selective inhibitor of the 20S proteasome β5 subunit of Plasmodium falciparum. Pf20S-IN-1 exhibits antiparasitic activity against Plasmodium falciparum, with an EC50 of 20.1 nM against the Plasmodium falciparum W2 strain. Pf20S-IN-1 shows weak inhibitory effect on human 20S proteasome, has no obvious toxicity to human foreskin fibroblasts (HFF), and has a selectivity index > 25000. Pf20S-IN-1 can be used in malaria research.
    Pf20S-IN-1
  • HY-183045
    Bentioflumin 2566451-67-8
    Bentioflumin is a fluoroalkylthiobenzene acaricide with excellent leaf penetration, and its control validity period against mites exceeds 25 days. Bentioflumin can be used in studies related to mite infestation.
    Bentioflumin
  • HY-183066
    AChE-IN-115
    AChE-IN-115 is an acetylcholinesterase (AChE) inhibitor. AChE-IN-115 forms stable complexes with AChE from Spodoptera litura (tobacco cutworm) and Tribolium castaneum (red flour beetle). AChE-IN-115 exhibits insecticidal activity.
    AChE-IN-115
  • HY-183091
    Antifungal agent 159
    Antifungal agent 159 is an antifungal agent with broad-spectrum activity against phytopathogenic fungi. Antifungal agent 159 binds tightly to the active sites of exo-β-(1,3)-glucanase, topoisomerase II-DNA-nucleotide, dihydrofolate reductase, sterol 14-α demethylase and chitin synthase. Antifungal agent 159 can be used in studies related to phytopathogenic fungal infections.
    Antifungal agent 159
  • HY-183157
    HIV-1-IN-93 2366269-07-8
    HIV-1-IN-93 is a HIV-1 RNase H inhibitor with an IC50 of 6.09 μM. HIV-1-IN-93 shows low cytotoxicity and can be used in studies related to HIV-1 infection.
    HIV-1-IN-93
  • HY-183176
    Laurolinium acetate 146-37-2
    Laurolinium acetate is a cationic antimicrobial agent. Laurolinium acetate exerts activity against Gram-positive and Gram-negative bacteria, and fungi. Laurolinium acetate can be used for the research of microbial infection.
    Laurolinium acetate
  • HY-183178
    Teroxalene 14728-33-7 98%
    Teroxalene is a piperazine-based Schistosomicide. Teroxalene is used for the research of schistosomiasis.
    Teroxalene
  • HY-183238
    Antimalarial agent 61 98%
    Antimalarial agent 61 is an antimalarial agent. Antimalarial agent 61 disrupts hemoglobin breakdown in Plasmodium falciparum asexual blood stage trophozoites. Antimalarial agent 61 exerts antiplasmodial activity against Chloroquine (HY-17589A)-sensitive Plasmodium falciparum parasites. Antimalarial agent 61 can be used for the research of malaria.
    Antimalarial agent 61
  • HY-183528
    Anticoccidial agent-1 762172-81-6 98%
    Anticoccidial agent-1 is an imidazopyridine anticoccidial agent with an IC50 of 0.044. Anticoccidial agent-1 can be used for the research of coccidiosis.
    Anticoccidial agent-1
  • HY-183529
    Antitrypanosomal agent 31 551919-54-1 98%
    Antitrypanosomal agent 31 is an antitrypanosoma agent with a pEC50 of 6.4. Antitrypanosomal agent 31 inhibits GSK-3β, CDK-2, and CDK-4 with pIC50s of 5.8, 6.9, and 7.1, respectively. Antitrypanosomal agent 31 can be used for the research of human african trypanosomiasis.
    Antitrypanosomal agent 31
  • HY-183530
    p38 MAPK-IN-11 152121-51-2
    p38 MAPK-IN-11 is a CSBP (p38 MAPK) kinase inhibitor with IC50 values of 0.15 μM (binding activity) and 0.21 μM (inhibitory activity). p38 MAPK-IN-11 shows weak inhibitory activity against PKCα kinase, with an IC50 of 7.6 μM. p38 MAPK-IN-11 inhibits the production of IL-1. p38 MAPK-IN-11 also acts as a β-lactam antibiotic potentiator, but has no antibacterial activity itself.
    p38 MAPK-IN-11
  • HY-183532
    Anticoccidial agent-2 189442-08-8
    Anticoccidial agent-2 is an orally effective imidazole-based anticoccidial agent. Anticoccidial agent-2 exhibits activity against Eimeria tenella in chickens. Anticoccidial agent-2 can be used in research related to chicken cecal coccidiosis.
    Anticoccidial agent-2
Cat. No. Product Name / Synonyms Application Reactivity